Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
